Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
|
WALTHAM, Mass., March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals Inc.. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 financial results on Monday, March 8, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, March 8, to discuss the Company's financial results and provide a general business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following: Conference ID: 7949816 For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. Syndax Contacts Investor Contact SNDX-G
SOURCE Syndax Pharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:SNDX |
View original content: